UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) off The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~February~~October 74, 2017

PROTO SCRIPT PHARMACEUTICAL CORP. (Exact name of registrant as specified in charter)

(Exact name of registrant as specified in charter)

Nevada

333-175146

99-0363803

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

9830 6th Street, Suite 103

Rancho Cucamonga, California

91730

(Address of principal executive offices)

(Zip Code)

(855) 476-7679

Registrant’s telephone number

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

.o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

.o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)

.o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))

.o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))

Item 14.0102 Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review.

~~Entry~~On ~~into~~October a4, ~~Material~~2017, ~~Definitive~~Proto ~~Agreement~~Script Pharmaceutical Corp. (the “Company”) was notified from its registered public accounting firm (the “Auditor”) that the Auditor had provided the Company with consent to file the Company’s Form 10-K for the fiscal year ended December 31, 2016 which the Company previously filed with the Commission on September 20, 2017, prior to receiving final consent to file by the Auditor’s EQR Partner.

~~Item 3.02~~2

~~Unregistered Sales of Equity Securities.~~SIGNATURES

OnPursuant ~~February~~to ~~7, 2017, Proto Script Pharmaceutical Corp. (~~the ~~“Company”)~~requirements ~~and~~of ~~Michelle Rico (“Rico”),~~ the ~~Company’s~~Securities ~~sole~~Exchange ~~officer~~Act ~~and~~of ~~director~~1934, ~~entered into a Share Exchange Agreement (~~the ~~“Agreement”). Pursuant~~Registrant tohas ~~the~~duly ~~Agreement,~~caused ~~Rico~~this ~~agreed~~report to ~~exchange~~be ~~295,000,000~~signed ~~shares~~on ofits ~~common~~behalf ~~stock~~by ~~that she owns into 1,500,000 shares of Series A Preferred Stock. The Company will cancel~~ the ~~295,000,000~~undersigned ~~shares~~hereunto ofduly ~~common stock and returned them back to treasury~~authorized.

The shares of preferred stock to be issued pursuant to the Agreement, shall be issued in reliance upon an exemption from registration afforded under Section 4(a)(2) of the Securities Act for transactions by an issuer not involving a public offering, or Regulation D promulgated thereunder. The Agreement is an exempt transaction pursuant to Section 4(a)(2) of the Securities Act as the share exchange was a private transaction by the Company and did not involve any public offering.

	PROTO SCRIPT PHARMACEUTICAL CORP.

Date: October 19, 2017	By:	/s/ Michelle Rico
		Michelle Rico, President

~~SIGNATURES~~3

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	PROTO SCRIPT PHARMACEUTICAL CORP.
Date: February 15, 2017	By:	/s/ Michelle Rico
		Michelle Rico, President

Filing Compare · PROTO SCRIPT PHARMACEUTICAL CORP